Thông tin thuốc gốc
Chỉ định và Liều dùng
Hyperphenylalaninaemia due to phenylketonuria
Adult: As sapropterin dihydrochloride: Initially, 10 mg/kg once daily, preferably in the morning, adjusted according to desired phenylalanine levels. Usual maintenance dose: 5-20 mg/kg once daily.
Child: ≥4 years Same as adult dose.

Hyperphenylalaninaemia due to tetrahydrobiopterin (BH4) deficiency
Adult: As sapropterin dihydrochloride: Initially, 2-5 mg/kg once daily, preferably in the morning, adjusted according to desired phenylalanine levels. Max total dose: 20 mg/kg daily, may alternatively be given in 2-3 divided doses.
Child: ≥4 years Same as adult dose.
Hướng dẫn pha thuốc
Dissolve with 120-240 mL of water or apple juice.
Thận trọng
Patient with history of convulsions. Hepatic and renal impairment. Children. Pregnancy and lactation.
Tác dụng không mong muốn
Significant: Gastritis, hyperactivity, hypersensitivity reactions, hypophenylalaninaemia.
Gastrointestinal disorders: Diarrhoea, vomiting, abdominal pain, dyspepsia, nausea.
Nervous system disorders: Headache.
Respiratory, thoracic and mediastinal disorders: Upper respiratory tract infection, rhinorrhoea, cough, nasal congestion, pharyngolaryngeal pain.
Chỉ số theo dõi
Monitor serum phenylalanine and tyrosine levels at baseline, 1 week after treatment, then periodically and regularly thereafter; blood pressure, nutrient intake, psycho-motor development, signs and symptoms of gastritis, hyperactivity.
Quá liều
Symptoms: Headache and dizziness. Management: Symptomatic treatment.
Tương tác
Increased excitability, irritability and exacerbation of convulsion with levodopa. May increase the vasodilating effect of phosphodiesterase type-5 (PDE-5) inhibitors, glyceryl trinitrate, isosorbide dinitrate (ISDN). Decreased serum concentration with methotrexate, trimethoprim.
Tương tác với thức ăn
Increased absorption with food.
Tác dụng
Description: Sapropterin is a synthetic form of tetrahydrobiopterin (BH4), an endogenous cofactor for phenylalanine hydroxylase (PAH). PAH enzyme hydroxylates phenylalanine through an oxidative reaction to form tyrosine; PAH activity is absent or deficient in patients with phenylketonuria. Sapropterin enhances the activity of residual PAH hence, improves normal phenylalanine metabolism and decreases serum phenylalanine level concentration.
Onset: Within 24 hours.
Duration: 24 hours.
Absorption: Increased absorption with food. Time to peak plasma concentration: 3-4 hours.
Distribution: Distributed mainly to the kidneys, adrenal glands, spleen and liver.
Metabolism: Metabolised in the liver by dihydrofolate reductase and dihydropteridine reductase to dihydrobiopterin and dihydroxanthopterin as main metabolites.
Excretion: Mainly via faeces; urine (small amount). Elimination half-life: Approx 7 hours (range: 4-17 hours).
Đặc tính

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Sapropterin, CID=135398654, (accessed on Jan. 23, 2020)

Bảo quản
Store between 20-25°C. Protect from moisture.
Any unused portions should be disposed of in accordance with local requirements.
Phân loại MIMS
Các thuốc khác ảnh hưởng đến chuyển hóa
Phân loại ATC
A16AX07 - sapropterin ; Belongs to the class of various alimentary tract and metabolism products.
Tài liệu tham khảo
Anon. Sapropterin. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. Accessed 04/06/2018.

Anon. Sapropterin. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 04/06/2018.

Buckingham R (ed). Sapropterin Hydrochloride. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 04/06/2018.

Joint Formulary Committee. Sapropterin Dihydrochloride. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. Accessed 04/06/2018.

Kuvan 100 mg Soluble Tablets (BioMarin International Limited). European Medicines Agency [online]. Accessed 04/06/2018.

Kuvan Tablet (BioMarin Pharmaceutical Inc.). DailyMed. Source: U.S. National Library of Medicine. Accessed 04/06/2018.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Sapropterin từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2023 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in